Novo Nordisk Pharmatech A/S — Credit Rating and Financial Key Figures

Novo Nordisk Pharmatech A/S (CVR number: 13246149) is a company from KØGE. The company reported a net sales of 956 mDKK in 2024, demonstrating a growth of 8.6 % compared to the previous year. The operating profit percentage was at 7.7 % (EBIT: 73.5 mDKK), while net earnings were 60.6 mDKK. The profitability of the company measured by Return on Assets (ROA) was 4.8 %, which can be considered decent and Return on Equity (ROE) was 5.8 %, which can be considered decent. The equity ratio, a key indicator for solidity, stood at 66.2 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. Novo Nordisk Pharmatech A/S's liquidity measured by quick ratio was 0.9 which is at a modest level. Thus, the company's liquid assets are in relative balance with its short-term liabilities, indicating a moderate liquidity position. While it's likely to meet its current obligations, financial flexibility may be constrained, and unexpected costs could pose challenges.